- Home
- RFL vs OMGA Comparison
RFL vs OMGA Comparison
Compare RFL & OMGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RFL
- OMGA
- Stock Information
- Founded
- RFL 2017
- OMGA 2017
- Country
- RFL United States
- OMGA United States
- Employees
- RFL N/A
- OMGA N/A
- Industry
- RFL Real Estate
- OMGA Biotechnology: Pharmaceutical Preparations
- Sector
- RFL Finance
- OMGA Health Care
- Exchange
- RFL Nasdaq
- OMGA Nasdaq
- Market Cap
- RFL 55.3M
- OMGA 53.6M
- IPO Year
- RFL N/A
- OMGA 2021
- Fundamental
- Price
- RFL $1.84
- OMGA $0.89
- Analyst Decision
- RFL
- OMGA Strong Buy
- Analyst Count
- RFL 0
- OMGA 5
- Target Price
- RFL N/A
- OMGA $9.20
- AVG Volume (30 Days)
- RFL 27.4K
- OMGA 256.8K
- Earning Date
- RFL 12-27-2024
- OMGA 11-14-2024
- Dividend Yield
- RFL N/A
- OMGA N/A
- EPS Growth
- RFL N/A
- OMGA N/A
- EPS
- RFL N/A
- OMGA N/A
- Revenue
- RFL $697,000.00
- OMGA $8,095,000.00
- Revenue This Year
- RFL N/A
- OMGA $181.29
- Revenue Next Year
- RFL N/A
- OMGA N/A
- P/E Ratio
- RFL N/A
- OMGA N/A
- Revenue Growth
- RFL 151.62
- OMGA 185.04
- 52 Week Low
- RFL $1.29
- OMGA $0.75
- 52 Week High
- RFL $2.50
- OMGA $6.30
- Technical
- Relative Strength Index (RSI)
- RFL 45.87
- OMGA 45.10
- Support Level
- RFL $1.74
- OMGA $0.83
- Resistance Level
- RFL $1.92
- OMGA $1.02
- Average True Range (ATR)
- RFL 0.09
- OMGA 0.10
- MACD
- RFL -0.00
- OMGA 0.01
- Stochastic Oscillator
- RFL 40.91
- OMGA 42.31
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.
About OMGA Omega Therapeutics Inc.
Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using epigenomic controllers, Omega is seeking to transform the practice of human medicine through selective and direct control of the human genome to treat and cure disease. It operates in the U.S.